1. Prophylaxis against NSAID-induced GI effects is recommended for select patients

   Newsletter Article 01 February 2013 Pages: 1 - 1

2. Ofloxacin - the Japanese experience

   Newsletter Article 01 February 2013 Pages: 1 - 1

3. There are lessons to be learnt from isotretinoin teratogenicity

   Newsletter Article 01 February 2013 Pages: 2 - 2

4. ADRs of antihyperlipidaemics must be taken into consideration

   Newsletter Article 01 February 2013 Pages: 2 - 3

5. Allopurinol

   Newsletter Article 01 February 2013 Pages: 4 - 4

6. Alteplase/anistreplase/streptokinase

   Newsletter Article 01 February 2013 Pages: 4 - 4

7. Aluminium hydroxide

   Newsletter Article 01 February 2013 Pages: 4 - 4

8. Amphotericin B

   Newsletter Article 01 February 2013 Pages: 4 - 4

9. Anistreplase see Alteplase/anistreplase/streptokinase

   Newsletter Article 01 February 2013 Pages: 5 - 5

10. Antineoplastics

    Newsletter Article 01 February 2013 Pages: 5 - 5

11. Atenolol overdose

    Newsletter Article 01 February 2013 Pages: 5 - 5

12. Azapropazone see Warfarin interaction

    Newsletter Article 01 February 2013 Pages: 5 - 5

13. Barium sulfate

    Newsletter Article 01 February 2013 Pages: 5 - 5

14. Busulfan

    Newsletter Article 01 February 2013 Pages: 5 - 5

15. Captopril overdose

    Newsletter Article 01 February 2013 Pages: 5 - 5

16. Carbamazepine

    Newsletter Article 01 February 2013 Pages: 5 - 5

17. Carboplatin

    Newsletter Article 01 February 2013 Pages: 5 - 6

18. Carmofur

    Newsletter Article 01 February 2013 Pages: 6 - 6

19. Ciprofloxacin

    Newsletter Article 01 February 2013 Pages: 6 - 6

20. Clofibrate

    Newsletter Article 01 February 2013 Pages: 6 - 6

21. Cyclophosphamide

    Newsletter Article 01 February 2013 Pages: 6 - 6

22. Cyclosporin

    Newsletter Article 01 February 2013 Pages: 6 - 7

23. Diclofenac

    Newsletter Article 01 February 2013 Pages: 7 - 7

24. Dipyrone

    Newsletter Article 01 February 2013 Pages: 7 - 7

25. Doxycycline

    Newsletter Article 01 February 2013 Pages: 7 - 7

26. Enalapril

    Newsletter Article 01 February 2013 Pages: 7 - 7

27. Epinephrine see Polidocanol/epinephrine

    Newsletter Article 01 February 2013 Pages: 7 - 7

28. Erythromycin see Lovastatin interaction

    Newsletter Article 01 February 2013 Pages: 7 - 7

29. Ethambutol

    Newsletter Article 01 February 2013 Pages: 7 - 7

30. FK 506

    Newsletter Article 01 February 2013 Pages: 7 - 7

31. Ganciclovir

    Newsletter Article 01 February 2013 Pages: 8 - 8

32. Hydrochlorothiazide +; triamterene

    Newsletter Article 01 February 2013 Pages: 8 - 8

33. Ibuprofen

    Newsletter Article 01 February 2013 Pages: 8 - 8

34. Immunoglobulin

    Newsletter Article 01 February 2013 Pages: 8 - 8

35. Iododoxorubicin

    Newsletter Article 01 February 2013 Pages: 8 - 9

36. Isotretinoin

    Newsletter Article 01 February 2013 Pages: 9 - 9

37. Lovastatin interaction

    Newsletter Article 01 February 2013 Pages: 9 - 9

38. Mesalazine

    Newsletter Article 01 February 2013 Pages: 9 - 9

39. Methamphetamine abuse

    Newsletter Article 01 February 2013 Pages: 9 - 9

40. Methotrexate

    Newsletter Article 01 February 2013 Pages: 9 - 10

41. Methylergometrine

    Newsletter Article 01 February 2013 Pages: 10 - 10

42. Mianserin

    Newsletter Article 01 February 2013 Pages: 10 - 10

43. Mitomycin

    Newsletter Article 01 February 2013 Pages: 10 - 10

44. Morphine

    Newsletter Article 01 February 2013 Pages: 10 - 11

45. Pentamidine

    Newsletter Article 01 February 2013 Pages: 11 - 11

46. Phenylephrine

    Newsletter Article 01 February 2013 Pages: 11 - 11

47. Polidocanol/epinephrine

    Newsletter Article 01 February 2013 Pages: 11 - 11

48. Prednicarbate

    Newsletter Article 01 February 2013 Pages: 11 - 11

49. Simvastatin

    Newsletter Article 01 February 2013 Pages: 11 - 11

50. Soya oil emulsion

    Newsletter Article 01 February 2013 Pages: 11 - 11